

Resource Summary Report

Generated by [nidm-terms](#) on Aug 9, 2026

PerCP/Cyanine5.5 anti-mouse CD4

RRID:AB_893324

Type: Antibody

Proper Citation

BioLegend Cat# 100434, RRID:AB_893324

Antibody Information

URL: http://antibodyregistry.org/AB_893324

Proper Citation: BioLegend Cat# 100434, RRID:AB_893324

Target Antigen: CD4

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-mouse CD4

Description: This monoclonal targets CD4

Target Organism: mouse

Clone ID: Clone GK1.5

Antibody ID: AB_893324

Vendor: BioLegend

Catalog Number: 100434

Alternative Catalog Numbers: 100433

Record Creation Time: 20250819T223909+0000

Record Last Update: 20250820T025238+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-mouse CD4.

No alerts have been found for PerCP/Cyanine5.5 anti-mouse CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 73 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Ronkina N, et al. (2026) Septin7 is essential in early hematopoiesis, but redundant at later stages. Life science alliance, 9(10).

Suzuki K, et al. (2026) Targeting the $\alpha 5$ Integrin Modifies the TGF β -Rich Tumor Microenvironment of Pancreatic Cancer. Cancer research, 86(15), 3801.

Zhu L, et al. (2026) Bach2 antagonizes leukotriene B4-Ltb4r1-JunB signaling to constrain Tfh13 cell differentiation. Cell reports, 45(4), 117220.

Yao L, et al. (2026) Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine, 102928.

Dong P, et al. (2026) Enhanced HIF-1 α cooperation by a human ROR γ t mutant potentiates Th17 pathogenicity. Cell reports, 45(4), 117123.

Hu M, et al. (2026) Activated T cell extracellular vesicle DNA transfer enhances antigen presentation and anti-tumor immunity. Cancer cell, 44(5), 965.

Ai ZE, et al. (2026) Targeting ADAR1 p150 triggers tumor inhibition and antitumor immunity to overcome immunotherapy resistance. iScience, 29(6), 115978.

Song X, et al. (2026) MHC-II-restricted neoantigen vaccine reverses immune microenvironment and overcomes resistance to immune-checkpoint inhibitors in cold tumors. Med (New York, N.Y.), 7(1), 100936.

Li B, et al. (2026) Leveraging intratumoral probiotics for pancreatic cancer immunotherapy via xenophagy. Cell host & microbe, 34(4), 657.

Tumanov AV, et al. (2026) Lymphotoxin-beta receptor controls the development of chronic pain. Cell reports, 45(4), 117269.

Wu S, et al. (2026) Immunotherapy-based combination remodels the immunosuppressive microenvironment and enhances efficacy in advanced SMARCA4-deficient non-small cell lung cancer. Cancer letters, 657, 218702.

Bian Q, et al. (2025) Maternal natural killer cells drive neuroimmune disorders in offspring through aberrant secretion of extracellular granzyme B. *Immunity*, 58(6), 1502.

Lee W, et al. (2025) Neutrophil extracellular traps promote pre-metastatic niche formation in the omentum by expanding innate-like B cells that express IL-10. *Cancer cell*, 43(1), 69.

Kunze-Schumacher H, et al. (2025) High-resolution mapping of cell cycle dynamics during steady-state T cell development and regeneration in vivo. *Cell reports*, 44(1), 115132.

Zhou Q, et al. (2025) Vorapaxar enhanced mitochondria-associated ferroptosis primes cancer immunotherapy via targeting FOXO1/HMOX1 axis. *Cell reports. Medicine*, 102371.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8⁺ T cells. *Immunity*, 58(10), 2472.

Dalangood S, et al. (2025) Cancer-associated adipocytes mediate CD8⁺T cell dysfunction via FGF21-driven lipolysis. *Cell reports*, 44(11), 116526.

Gawish R, et al. (2025) Filamin A editing in myeloid cells reduces intestinal inflammation and protects from colitis. *The Journal of experimental medicine*, 222(9).

de Aquino MTP, et al. (2025) Glutamate receptor-T cell receptor signaling potentiates full CD8⁺ T cell activation and effector function in tumor immunity. *iScience*, 28(10), 112772.

Sun J, et al. (2025) Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. *Cancer immunology research*, 13(3), 400.